Abbott DeFT Response™ technology allows physicians to customize rescue therapy to each patient’s unique cardiac physiology and changing condition.
DeFT Response technology preserved a 10 J safety margin for 100% of the Abbott patients.
17% of the fixed-tilt group of patients with competitive devices had compromised the 10 J safety margin.
Group A: Adjustable
Group B: Fixed-tilt
Boston Scientific, Medtronic, Biotronik
|14J||—||20 (59%)||—||24 (34%)|
|21J||7 (20%)||3 (9%)||17 (24%)||8 (11%)|
|25J||1 (3%)||3 (9%)||7 (10%)||3 (4%)|
|31J||0||0||6 (8%)||4 (6%)|
Method: Analysis of DFT levels for 105 patients implanted with a single coil lead between Aug 2007 and Aug 2010.
DFT Testing: VF induced by synchronized T-wave shock or direct current pulse. If initial shock failed, second shock delivered at highest energy within 10 J safety margin of device. If unsuccessful, a subcutaneous coil implanted and DFT test repeated. Note: the RV-coil was specifically programmed as an anode in all devices.
*Applies to single coil systems.